Home Biosimilar Antibodies Protein Tyrosine Kinase Axl Enapotamab (Anti-AXL / UFO)
For research use only. Not for use in humans.

Enapotamab (Anti-AXL / UFO)

Synonyms: UFO， Tyro7

Enapotamab(Anti-AXL / UFO) is a highly specific rabbit polyclonal antibody that targets receptor tyrosine kinase AXL (UFO). It demonstrates potent activity in immunotherapeutic strategy for the treatment of sarcomas. MW :145.42 KD.

Enapotamab (Anti-AXL / UFO)

Click to purchase the isotype control of Enapotamab (Anti-AXL / UFO)

Quality Control

Batch: A258601 Purity: 99% Protein concentration: 7.85mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation Axl Others
BMS-777607 63 RON,Met,Tyro3
Bemcentinib (R428) 132
XL092 0 VEGFR2,MER,MET
UNC2025 7 FLT3,Mer,TrkA
Ningetinib 0 VEGFR2,c-Met
Tamnorzatinib (ONO-7475) 7 Mer,FLT3
RU-301 0
Sitravatinib (MGCD516) 10 DDR2,EPHA3,Mer
CEP-40783 (RXDX-106) 7 c-Met,Tyro3,MER
S49076 1 Met,Mer,FGFR3
Merestinib (LY2801653) 11 DDR1,Met,DDR2
SGI-7079 4 YES,Mer,Met
UNC2025 HCl 11 Mer,FLT3,Tyro3
Dubermatinib(TP-0903) 19
NPS-1034 6 Met
LDC1267 14 Mer,Tyro3
PF-07265807 0 Mer
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Enapotamab(Anti-AXL / UFO) is a highly specific rabbit polyclonal antibody that targets receptor tyrosine kinase AXL (UFO). It demonstrates potent activity in immunotherapeutic strategy for the treatment of sarcomas. MW :145.42 KD.

Product Details

CAS No.  1912423-61-0
Molecular Weight 145.42 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03816137 COMPLETED HIV-1-infection Imperial College London 2019-03-19 PHASE1
NCT04046978 WITHDRAWN Virus Diseases Imperial College London 2019-12-11
NCT02988817 COMPLETED Ovarian Cancer; Cervical Cancer; Endometrial Cancer; Non Small Cell Lung Cancer (NSCLC); Thyroid Cancer; Melanoma; Sarcoma; Solid Tumors Genmab 2016-11-23 PHASE1; PHASE2

(data from https://clinicaltrials.gov, updated on 2024-11-05)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.